Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
2024年8月15日 - 5:30AM
Edgar (US Regulatory)
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
|
|
|
FORM
12b-25 |
SEC
File Number: 1-41475 |
|
NOTIFICATION
OF LATE FILING |
CUSIP
Number: 70424C 10 4 |
(Check
one) Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☒ Form 10-D ☐ Form
N-CEN ☐ Form N-CSR ☐
For
Period Ended: June 30, 2024
|
☐ |
Transition
Report on Form 10-K |
|
☐ |
Transition
Report on Form 20-F |
|
☐ |
Transition
Report on Form 11-K |
|
☐ |
Transition
Report on Form 10-Q |
For
the Transition Period Ended:________________________
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I - REGISTRANT INFORMATION
PAXMEDICA,
INC.
Full
Name of Registrant
Former
Name if Applicable
303
South Broadway, Suite 125
Address
of Principal Executive Office (Street and Number)
Tarrytown,
NY 10591
City,
State and Zip Code
PART
II - RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
|
(a) |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution reported on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and |
|
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III - NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
PaxMedica,
Inc. requires additional time to complete the document preparation and related procedures required to finalize and file its Form 10-Q.
(Attach
Extra Sheets if Needed)
PART
IV - OTHER INFORMATION
(1) |
Name
and telephone number of person to contact in regard to this notification |
Stephen
D. Sheldon |
|
(914) |
|
987-2876 |
(Name) |
|
(Area
Code) |
|
(Telephone
Number) |
(2) |
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s). ☒ Yes ☐ No |
|
|
(3) |
It
is anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earning statements to be included in the subject report or portion thereof? ☒ Yes ☐ No |
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made. |
The
Form 10-Q will disclose a net loss of approximately $3.4 million for the three months ended June 30, 2024 in comparison to a net loss
of $3.5 million for the three months ended June 30, 2023. The Form 10-Q will also disclose a net loss of approximately $7.1 million for
the six months ended June 30, 2024 in comparison to a net loss of $7.3 million for the six months ended June 30, 2023.
PAXMEDICA,
INC.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
August 14, 2024 |
By: |
/s/
Stephen D. Sheldon |
|
|
Stephen
D. Sheldon |
|
|
Chief
Operating Officer and Chief Financial Officer |
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title
of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant
by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf
of the registrant shall be filed with the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). |
PaxMedica (PK) (USOTC:PXMD)
過去 株価チャート
から 7 2024 まで 8 2024
PaxMedica (PK) (USOTC:PXMD)
過去 株価チャート
から 8 2023 まで 8 2024